What Is Amylin? The Hormone Behind New Weight-Loss Drugs
Amylin weight loss drugs are the next big idea in obesity research. Learn what amylin is, what the new 2026 trials reported and what still isn’t known.
News
-
-
Why the FDA Sent Warning Letters to Peptide Sellers in 2026
Eight online peptide sellers got FDA warning letters in 2026. Here’s what the FDA said, the four mistakes behind every letter and what’s happened since.
-
Viking’s VK2735 Maintenance Study: What the Results Show
Viking Therapeutics reported top-line results from VK2735-102, a randomized maintenance study of its investigational dual GLP-1/GIP agonist — a separate data point from Lilly’s retatrutide TRIUMPH-2 results.
-
FDA’s Warning Letter to Empower Pharmacy, Explained
A September 18 FDA warning letter to Empower Pharmacy describes alleged Section 503A failures involving compounded products FDA characterized as copies of marketed semaglutide and tirzepatide products. The action offers a documented view of the agency’s current compounding-enforcement posture.
-
Retatrutide TRIUMPH-2 Phase 3 Results: What Lilly Reported
Lilly’s newly announced 80-week TRIUMPH-2 findings add a pivotal clinical-data update to retatrutide research, while the compound remains investigational and detailed results await scientific presentation.
-
FDA Approves Rusfertide, a First-of-Its-Kind Peptide Drug
FDA’s August 28 approval of Mimrylo (rusfertide), an injectable hepcidin peptide mimetic, adds a first-in-class product to the peptide-therapeutics field. The decision was supported by the Phase 3 VERIFY study and is distinct from the research-only peptide market.
-
FDA Panel Votes to Back BPC-157, KPV and TB-500 for Compounding
The FDA Pharmacy Compounding Advisory Committee voted narrowly in July 2026 to recommend six peptides including BPC-157, KPV, and TB-500 for addition to the 503A Bulk Drug Substances List, marking a pivotal moment in peptide regulatory research.
-
Can Aging Be Reversed? David Sinclair’s Research, Explained
Harvard professor David Sinclair’s lab has demonstrated that aging is not simply wear and tear — it is an information problem. In 2026, the FDA cleared the first human trial of cellular reprogramming technology. Here is what that means for longevity research, and how peptides fit into the picture.
-
What Is the 503A Bulks List? A Plain-English Guide
The 503A Bulks List is a regulatory designation that allows licensed compounding pharmacies to prepare substances for individual patients without FDA approval. Understanding this pathway is essential for researchers tracking the evolving legal status of peptides like BPC-157, KPV, and TB-500.
-
The Research Peptide Market in 2026: Who’s Left After the Shakeout
The research peptide market has undergone a significant consolidation in 2025–2026. The closure of Peptide Sciences, FDA enforcement actions against multiple vendors, and new regulatory scrutiny have reduced the number of active suppliers while raising the bar for quality documentation and compliance.